Prevention of development of dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat by the new nonsteroidal antiestrogen EM-800 (SCH57050)

Breast Cancer Research and Treatment

Volumn 49, Issue 1, 1998, Pages 1-11

  Luo, Shouqi ^a   Labrie, Claude ^a   Bélanger, Alain ^a   Candas, Bernard ^a   Labrie, Fernand ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Antiestrogen; BMD; Bone mineral density; Breast cancer; Cholesterol; Estrogen sensitive; Lipids; Triglycerides

Indexed keywords

4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; ALKALINE PHOSPHATASE; ANDROSTENEDIOL; ANDROSTENEDIONE; ANTIESTROGEN; CALCIUM ION; CHOLESTEROL; CREATININE; DIMETHYLBENZ[A]ANTHRACENE; ESTRADIOL; HYDROXYPROLINE; LIPID; PHOSPHORUS; TESTOSTERONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANDROSTENEDIONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; BREAST CARCINOGENESIS; CALCIUM URINE LEVEL; CANCER INCIDENCE; CHEMICAL CARCINOGENESIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE URINE LEVEL; ESTRADIOL BLOOD LEVEL; FEMALE; FEMUR; HYDROXYPROLINE URINE LEVEL; LIPID BLOOD LEVEL; LUMBAR SPINE; NONHUMAN; PRIORITY JOURNAL; RAT; SKELETON; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION; UTERUS WEIGHT;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; BENZOPYRANS; BODY WEIGHT; BONE AND BONES; BONE DENSITY; ESTROGEN ANTAGONISTS; FEMALE; LIPIDS; MAMMARY NEOPLASMS, EXPERIMENTAL; ORGAN SIZE; OVARY; PRODRUGS; PROPIONATES; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; UTERUS; VAGINA;

EID: 0031813087     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005928814521     Document Type: Article

References (71)

1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer Statistics 1997. CA Cancer J Clin 47: 5-27, 1997
2. Henderson BE, Ross R, Bernstein L: Estrogens as a cause of human cancer. The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 48: 246-253, 1988
3. Jordan VC: Use of the DMBA-induced rat mammary carcinoma system for the evaluation of Tamoxifen as a potential adjuvant therapy. Rev Endocr Relat Cancer Suppl 49: 55, 1978
4. Jordan VC: Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinoma. Eur J Cancer 12: 419-424, 1976
5. Kawamura I, Mizota T, Kondo N, Shimomura K, Kohsaka M: Antitumor effects of droloxifene, a new antiestrogen drug, against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats. Jpn J Pharmacol 57: 215-224, 1991
6. Smigel K: Nearly 3,000 randomized in North American prevention trial. J Natl Cancer Inst 84: 1555, 1992
7. Vanchieri C: Breast cancer prevention study initiated in Italy. J Natl Cancer Inst 84: 1555-1556, 1992
8. Powles TJ, Jones AL, Ashley SE, O'Brien MER, Tidy VA, Treleavan J, Cosgrove D, Nash AG, Sacks N, Baum M, McKinna JA, Davey JB: The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 31: 73-82, 1994
9. Huggins C, Grand LC, Brillantes FP: Mammary cancer induced by a single feeding of polynuclear hydrocarbons, and its suppression. Nature 189: 204-207, 1961
10. Welsch CW: Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: a review and tribute to Charles Brenton Huggins. Cancer Res 45: 3415-3443, 1985
11. Leung BS, Sasaki GH, Leung JS: Estrogen-prolactin dependency in 7,12-dimethylbenz(a)anthracene-induced tumors. Cancer Res 35: 621-627, 1975
12. Asselin J, Kelly PA, Caron MG, Labrie F: Control of hormone receptor levels and growth of 7,12-dimethylbenz(a) anthracene-induced mammary tumors by estrogens, progesterone and prolactin. Endocrinology 101: 666-671, 1977
13. Asselin J, Labrie F: Effects of estradiol and prolactin on steroid receptor levels in 7,12-dimethylbenz(a)anthracene-induced mammary tumors and uterus in the rat. J Steroid Biochem 9: 1079-1082, 1978
14. Li S, Lévesque C, Geng CS, Yan X, Labrie F: Inhibitory effects of medroxyprogesterone acetate (MPA) and the pure antiestrogen EM-219 on estrone (E1)-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Breast Cancer Res Treat 34: 147-159, 1995
15. Labrie F, Li S, Bélanger A, Côté J, Mérand Y, Lepage M: Controlled release low dose medroxyprogesterone acetate (MPA) inhibits the development of mammary tumors induced by dimethylbenz(a)anthracene in the rat. Breast Cancer Res Treat 26: 253-265, 1993
16. Kelly PA, Asselin J, Labrie F: Endocrine regulation of growth and hormone receptor levels in DMBA-induced mammary tumors. In: Thompson EB, Lippman ME (eds) Steroid Receptors and the Management of Cancer. CRC Press, Inc., Boca Raton, Florida, Vol 2, 1979, pp 3-29
17. Kelly PA, Asselin J, Caron MG, Raynaud JP, Labrie F: High inhibitory activity of a new antiestrogen, RU16117 (11α-methoxy-ethinyl estradiol) on the development of dimethylbenz(a)anthracene-induced mammary tumors. Cancer Res 37: 76-81, 1977
18. Dauvois S, Labrie F: Effect of adrenal estrogens on the growth of dimethylbenz(a)anthracene-induced mammary carcinoma in the rat. In: Bradlow HL, d'Aquino S, Labrie F (eds) Steroid Formation, Degradation and Action in Peripheral Tissues, Normal and Neoplastic Tissues. Ann New York Acad Sci, Vol 595, 1990, pp 416-418
19. Dauvois S, Spinola PG, Labrie F: Additive inhibitory effects of bromocriptine (CB-154) and medroxyprogesterone acetate (MPA) on dimethylbenz(a)anlhracene (DMBA)-induced mammary tumors in the rat. Eur J Cancer Clin Oncol 25: 891-897, 1989
20. Labrie F, Kelly PA, Asselin J, Raynaud JP: Potent inhibitory activity of a new antiestrogen, RU16117, on the development and growth of DMBA-induced rat mammary adenocarcinoma. In: Band G, Israel L (eds) Breast Cancer, A Multidisciplinary Approach. Recent Results in Cancer Research. Springer-Verlag, New York, vol 57, 1976, pp 109-120
21. Jordan VC, Allen KE: Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 16: 231-251, 1980
22. Li S, Yan X, Bélanger A, Labrie F: Prevention by dehydroepiandrosterone of the development of mammary carcinoma induced by 7,12-dimethylbenz(a)anthracene (DMBA) in the rat. Breast Cancer Res Treat 29: 203-217, 1993
23. Gordon T, Kannel WB, Hortland MC, McNamara PM: Menopause and coronary heart disease: The Framingham Study. Ann Int Med 89: 157-161, 1978
24. Riggs BL: Overview of osteoporosis. West J Med 154: 63-77, 1991
25. Cummings SR: Evaluating the benefits and risks of postmenopausal hormonal therapy. Am J Med 91 (Suppl. 5B): 14S-18S, 1991
26. Luo S, Martel C, Sourla A, Gauthier S, Mérand Y, Bélanger A, Labrie C, Labrie F: Comparative effects of 28-day treatment with the new antiestrogen EM-800 and tamoxifen on estrogen-sensitive parameters in the intact mouse. Int J Cancer 73: 381-391, 1997
27. Luo S, Sourla A, Labrie C, Bélanger A, Labrie F: Combined effects of dehydroepiandrosterone and EM-800 on bone mass, serum lipids, and the development of dimethylbenz(a) anthracene (DMBA)-induced mammary carcinoma in the rat. Endocrinology 138: 4435-4444, 1997
28. Luo S, Stojanovic M, Labrie C, Labrie F: Inhibitory effect of the novel antiestrogen EM-800 and medroxyprogesterone acetate (MPA) on estrone-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Int J Cancer 73: 580-586, 1998
29. Gauthier S, Caron B, Cloutier J, Dory YL, Favre A, Larouche D, Mailhot J, Quellet C, Schwerdtfeger A, Leblanc G, Martel C, Simard J, Mérand Y, Bélanger A, Labrie C, Labrie F: (S)-(+)-[4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl) ethoxy]phenyl]-2H-1-benzopyran-3-yl]phenyl]2,2-dimethylpropanoate (EM-800): a highly potent, specific and orally active non-steroidal antiestrogen. J Med Chem 40: 2117-2122, 1997
30. Simard J, Labrie C, Bélanger A, Gauthier S, Singh SM, Mérand Y, Labrie F: Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro. Int J Cancer 73: 104-111, 1997
31. Tremblay GB, Tremblay A, Copeland NG, Gilbert DJ, Jenkins NA, Labrie F, Giguere V: Cloning, chromosomal localization and functional analysis of the murine estrogen receptor β. Mol Endocrinol 11: 353-365, 1997
32. Podenphant J, Larsen NE, Christiansen C: An easy and reliable method for determination of urinary hydroxyproline. Clin Chim Acta 142: 145-148, 1984
33. Bélanger A, Labrie F, Angeli A: Unconjugated and glucuronide steroid levels in human breast cyst fluid. In: Angeli AL, Bradlow HL, Chasalow FI, Gogliotti L (eds) Biochemistry of Breast Cyst Fluid. Correlation with Breast Cancer Risk. Ann New York Sci, Vol 586, 1990, pp 93-100
34. Jordan VC: Antitumor activity of the antiestrogen ICI 46,474 (tamoxifen) in the dimethylbenz(a)anthracene (DMBA) induced rat mammary carcinoma model. J Steroid Biochem 5: 354 (Abstr 243), 1974
35. Fendl KC, Zimniski SJ: Role of tamoxifen in the induction of hormone-independent rat mammary tumors. Cancer Res 52: 235-237, 1992
36. Brunner N, Frandsen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, Lippman ME, Clarke R: MCF7/ LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res 53: 3229-3232, 1993
37. Bronzert DA, Greene GL, Lippman ME: Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY-117018. Endocrinology 117: 1409-1417, 1985
38. Gottardis MM, Jiang SY, Jeng MH, Jordan VC: Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 49: 4090-4093, 1989
39. Gottardis MM, Jordan VC: Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48: 5183-5187, 1988
40. Muss HB: Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res Treat 21: 15-26, 1992
41. Sylvester PW, Aylsworth CF, Van Vugt DA, Meites J: Effects of alterations in early hormonal environment on development and hormone dependence of carcinogen-induced mammary tumors in rats. Cancer Res 43: 5342-5346, 1983
42. Korach KS: Insights from the study of animals lacking functional estrogen receptor. Science 266: 1524-1527, 1994
43. Dipippo VA, Lindsay R, Powers CA: Estradiol and tamoxifen interactions with thyroid hormone in the ovariectomized-thyroidectomized rat. Endocrinology 136: 1020-1033, 1995
44. Ke HZ, Simmons HA, Pirie CM, Crawford TD, Thompson DD: Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology 136: 2435-2441, 1995
45. Russell JC, Amy RM, Graham S, Wenzel LM, Dolphin PJ: Effects of castration on hyperlipidemic, insulin resistant JCR:LA-corpulent rats. Atherosclerosis 100: 113-122, 1993
46. Black LJ, Sato M, Bowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kaufman RF, Bensch WR, Frolik CA, Termine JD, Bryant HU: Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93: 63-69, 1994
47. Weinstein I, Wilcox HG, Heimberg M: Effects of high-dose ethinyl estradiol on serum concentrations and hepatic secretion of the very-low density lipoprotein, triglycerol, cholesterol, and apolipoprotein A-I in the rat. Biochim Biophys Acta 876: 450-459, 1986
48. Windler EE, Kovanen PT, Chao YS, Brown MS, Havel RJ, Goldstein JL: The estradiol-stimulated lipoprotein receptor of rat liver. J Biol Chem 255: 10464-10471, 1980
49. Wilcox HG, Kenagy R, Weinstein I, Heimberg M: Alterations of plasma HDL lipids and apolipoproteins in female rats treated with ethynyl estradiol. Biochim Biophys Acta 666: 348-355, 1981
50. Chao YS, Windler EE, Chen GC, Havel RJ: Hepatic catabolism of rat and human lipoproteins in rats treated with 17α-ethinyl estradiol. J Biol Chem 254: 11360-11366, 1979
51. Davis RA, Roheim PS: Pharmacologically induced hypolipidemia. The ethinyl estradiol-treated rat. Atherosclerosis 30: 293-299, 1978
52. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR: Menopause and risk factors for coronary heart disease. N Engl J Med 321: 641-646, 1989
53. Bruning PF, Bonfrer JM, Hart AA, de Jong Bakkar M, Linders D, van Loon J, Nooyen WJ: Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer 58: 497-499, 1988
54. Love RR, Wiebe DA, Newcomb PA, Cameron L, Leventhal H, Jordan VC, DeMets J: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 115: 860-864, 1991
55. Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC, Carbone PP, DeMets DL: Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 82: 1327-1332, 1990
56. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks F: Effects of postmenopausal estrogen replacement on the concentration and metabolism of plasma lipoproteins. N Engl J Med 325: 1196-1204, 1991
57. Barrett-Connor E: Estrogen and estrogen-progestogen replacement therapy and cardiovascular diseases. Am J Med 95 (Suppl. 5A): 40S-43S, 1993
58. Staels BJ, Auwerx L, Chan L, von Tol A, Rosseneu M, Verhoeven G: Influence of development, estrogens, and food intake on apolipoprotein A-I, A-II and E mRNA in rat liver and intestine. J Lipid Res 30: 1139-1145, 1989
59. Haffner SM, Valdez RA: Endogenous sex hormones: impact on lipids, lipoproteins, and insulin. Am J Med 98 (Suppl. 1A): 40S-47S, 1995
60. LaRosa JC: Androgens and women's health: genetic and epidemiologic aspects of lipid metabolism. Am J Med 98 (Suppl. 1A): 22S-26S, 1995
61. Kristensen B, Ejlertsen B, Dalgaard P, Larsen L, Holmegaard SN, Transbol I, Mouridsen HT: Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol 12: 992-997, 1994
62. Jordan VC, Phelps E, Lindgren JV: Effects of antiestrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 10: 31-35, 1987
63. Turner RT, Wakley GK, Hannon KS, Bell NH: Tamoxifen inhibits osteoclast mediated resorption of trabecular bone in ovarian hormone deficient rats. Endocrinology 122: 1146-1150, 1988
64. Fentiman IM, Caleffi M, Rodin A, Murby B, Fogelman I: Bone mineral content of women receiving tamoxifen for mastalgia. Br J Cancer 60: 262-264, 1989
65. Turner CH, Sato M, Bryant HU: Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology 135: 2001-2005, 1994
66. Kanis JA: Treatment of osteoporosis in elderly women. Am J Med 98 (Suppl. 1A): 60S-66S, 1995
67. Prestwood KM, Pilbeam CC, Burleson JA, Woodiel FN, Delmas PD, Deftos U, Raisz LG: The short term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab 79: 366-371, 1994
68. Steiniche T, Hasling C, Charles P, Eriksen EF, Mosekilde L, Melsen F: A randomized study on the effects of estrogen/ gestagen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis. Bone 10: 313-320, 1989
69. Meunier PJ, Salson C, Mathieu L: Skeletal distribution and biochemical parameters of Paget's disease. Clin Orth Relat Res 217: 33-44, 1987
70. Nordin BEC: Diagnostic procedures in disorders of calcium metabolism. Clin Endocrinol (Oxf) 8: 55-67, 1978
71. Lauffenburger T, Olah AJ, Dambacher MA, Guncaga J, Lentner C, Haas HG: Bone remodeling and calcium metabolism: a correlated histomorphometric, calcium kinetic, and biochemical study in patients with osteoporosis and Paget's disease. Metabolism 26: 589-606, 1977